ATOS — ATOSSA THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1488039 ·
Last close
$2.42
Market Cap
$24.15M
52W High
$19.35
52W Low
$1.70
ADV30
59,429
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -8,694,000 | -8,491,000 | 32,281,000 | 26,094,000 | 5,451,000 |
| Mar 2026 | 0 | — | -9,870,000 | -9,589,000 | 37,943,000 | 31,718,000 | 7,457,000 |
| Dec 2025 | 0 | — | -11,436,000 | -10,937,000 | 47,608,000 | 41,299,000 | 8,255,000 |
| Sep 2025 | 0 | — | -9,251,000 | -8,692,000 | 58,012,000 | 51,845,000 | 8,225,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-33,384,000
Investing CF
$-14,000
Financing CF
$0
CapEx
$-23,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-3.96
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-256,151,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-39,597,000
Pretax Income TTM
$-37,641,000
Interest Exp TTM
—
Analysts
3
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -37,141,000 | -34,770,000 | 47,608,000 | 8,255,000 | 39,353,000 | -29,762,000 |
| Dec 2024 | 0 | -27,621,000 | -25,504,000 | 76,444,000 | 4,967,000 | 71,477,000 | -21,030,000 |
| Dec 2023 | 0 | -31,377,000 | -30,094,000 | 96,252,000 | 5,236,000 | 91,016,000 | -20,941,000 |
| Dec 2022 | 0 | -27,691,000 | -26,960,000 | 123,532,000 | 5,568,000 | 117,964,000 | -20,760,000 |
TTM Snapshot
Revenues TTM
$1,966,000
NetIncome TTM
$-37,641,000
OpCashFlow TTM
—
Assets (Latest)
$37,943,000
Forward EPS
$-4.38
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.00 · spot: $2.42 · call volume: 51 · put volume: 5
Expected Move to 2027-01-15:
±$0.89
(36.78%) —
implied range
$1.53 –
$3.31
· ATM straddle on $2.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KYNB | KYNTRA BIO, INC. | $24.13M | $5.96 | — |
| JAGX | Jaguar Health, Inc. | $23.41M | $4.53 | — |
| OPTH | Optimi Health Corp. | $23.39M | $4.09 | — |
| BYSI | BeyondSpring Inc. | $25.04M | $0.61 | — |
| TXMD | TherapeuticsMD, Inc. | $23.26M | $2.01 | — |
News headlines (Yahoo Finance, 1h cache)
Atossa plans shareholder stake in potential PRV proceeds
2026-09-30 17:18 · Yahoo
Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher
2026-09-29 12:00 · Yahoo
Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging
2026-09-24 12:00 · Yahoo
Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
2026-08-07 12:45 · Yahoo
Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer
2026-07-28 12:30 · Yahoo
Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers
2026-07-21 12:30 · Yahoo
ATOS: Raises up to $16.5 Million in Registered Direct Offering
2026-07-01 13:08 · Yahoo
Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds
2026-06-12 21:30 · Yahoo
Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds
2026-06-11 12:00 · Yahoo
Atossa Therapeutics highlights Endoxifen progress as potential Breast Cancer treatment
2026-06-10 16:51 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.